Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Current Oncology Reports

• Publication date

  2022-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11912-022-01279-zPMID 35476177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management

  2021cited by this paper
• Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis

  2021cited by this paper
• Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2

  2021cited by this paper
• Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy

  2021cited by this paper
• Neurologic Adverse Events of Immune Checkpoint Inhibitors

  2021cited by this paper
• Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

  2021cited by this paper
• Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker

  2021cited by this paper
• Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes

  2021cited by this paper
• Immunophenotypical characterization of paraneoplastic neurological syndrome patients: a multicentric study

  2021cited by this paper
• Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis

  2021cited by this paper
• Paraneoplastic neurological syndromes: clinical presentations and management

  2021cited by this paper
• Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar Syndrome

  2021cited by this paper
• Central nervous system complications associated with immune checkpoint inhibitors

  2020cited by this paper
• Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France

  2020cited by this paper
• Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.

  2020cited by this paper
• A decade of immune-checkpoint inhibitors in cancer therapy

  2020cited by this paper
• What's happening in Neurology® Neuroimmunology & Neuroinflammation

  2020cited by this paper
• Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program

  2020cited by this paper
• Clinical significance of Kelch-like protein 11 antibodies

  2020cited by this paper
• Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum

  2020cited by this paper
• Understanding adverse events of immunotherapy: A mechanistic perspective

  2020cited by this paper
• Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes

  2020cited by this paper
• Paraneoplastic Neurological Syndromes: Study of Prevalence in a Province of the Lombardy Region, Italy

  2020cited by this paper
• Advances in cancer immunotherapy 2019 – latest trends

  2019cited by this paper
• Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival

  2019cited by this paper
• Paraneoplastic neurological syndromes: a single institution 10-year case series

  2019cited by this paper
• PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.

  2019cited by this paper
• Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors

  2019cited by this paper
• Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

  2019cited by this paper
• Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient.

  2019cited by this paper
• Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study

  2019cited by this paper
• Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck.

  2019cited by this paper
• Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

  2019cited by this paper
• Amphiphysin-IgG autoimmune neuropathy

  2019cited by this paper
• Phosphodiesterase 10A IgG

  2019cited by this paper
• Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG

  2019cited by this paper
• Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.

  2019cited by this paper
• This is a repository copy of Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

  2018cited by this paper
• Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme

  2018cited by this paper
• Paraneoplastic neuronal intermediate filament autoimmunity

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• The Positive Predictive Value of Onconeural Antibody Testing: A Retrospective Review

  2018cited by this paper
• Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

  2017cited by this paper
• Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes

  2017cited by this paper
• Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies

  2017cited by this paper
• Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.

  2017cited by this paper
• Improving the antibody-based evaluation of autoimmune encephalitis

  2017cited by this paper
• Diagnostics of paraneoplastic neurological syndromes

  2017cited by this paper
• Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies

  2017cited by this paper
• A clinical approach to diagnosis of autoimmune encephalitis.

  2016cited by this paper
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

  2016cited by this paper
• CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.

  2016cited by this paper
• Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

  2016cited by this paper
• Myasthenic crisis and polymyositis induced by one dose of nivolumab

  2016cited by this paper
• CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

  2016cited by this paper
• Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

  2016cited by this paper
• Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.

  2016cited by this paper
• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

  2016cited by this paper
• Pitfalls in the detection of CV2 (CRMP5) antibodies.

  2016cited by this paper
• Western blotting revisited: Critical perusal of underappreciated technical issues

  2015cited by this paper
• Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease

  2014cited by this paper
• Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.

  2014cited by this paper
• Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes

  2014cited by this paper
• Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study

  2014cited by this paper
• Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer

  2013cited by this paper
• Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies

  2013cited by this paper
• Treatment for paraneoplastic neuropathies.

  2012cited by this paper
• Paraneoplastic neurological syndromes.

  2012cited by this paper
• IL-18 induces PD-1-dependent immunosuppression in cancer.

  2011cited by this paper
• Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.

  2011cited by this paper
• New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.

  2011cited by this paper
• Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.

  2010cited by this paper
• SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.

  2009cited by this paper
• Paraneoplastic Neurological Syndromes: A Review

  2009cited by this paper
• Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?

  2009cited by this paper
• SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndrome

  2008cited by this paper
• Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.

  2008cited by this paper
• Stiff-person syndrome with amphiphysin antibodies

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Foxp3-dependent programme of regulatory T-cell differentiation

  2007cited by this paper
• Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma

  2007cited by this paper
• Paraneoplastic limbic encephalitis: diagnostic relevance of CSF analysis and total body PET scanning.

  2004cited by this paper
• Clinical analysis of anti-Ma2-associated encephalitis.

  2004cited by this paper
• Recommended diagnostic criteria for paraneoplastic neurological syndromes

  2004cited by this paper
• Paraneoplastic Encephalitis Associated With Cystic Teratoma Is Detected by Fluorodeoxyglucose Positron Emission Tomography With Negative Magnetic Resonance Image Findings

  2003cited by this paper
• Anti‐neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments

  2003cited by this paper
• Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease

  2003cited by this paper
• Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

  2001cited by this paper
• Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma.

  2001cited by this paper
• Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.

  2000cited by this paper
• Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone

  2000cited by this paper
• Advances in cancer immunotherapy.

  1999cited by this paper
• Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

  1992cited by this paper
• Diagnostic value of anti-neuronal antibodies for paraneoplastic disorders of the nervous system.

  1990cited by this paper
• Neuronal antinuclear antibody in sensory neuronopathy from lung cancer

  1985cited by this paper
• "Limbic encephalitis" and its association with carcinoma.

  1968cited by this paper

• Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

  2026cites this paper
• T Cell-Mediated Mechanisms of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors.

  2025cites this paper
• Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review

  2024cites this paper
• Anti-Hu antibody associated paraneoplastic neurological syndrome in a child with ganglioneuroblastoma: A rare case report and literature review

  2024cites this paper
• General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis

  2023cites this paper